PEOPLE ON THE MOVE
Mast Therapeutics
Mast Therapeutics, a San Diego biotech using molecular adhesion and sealant technology (MAST) technology to develop therapies for sickle cell disease, heart failure, and stroke, has made ex-MedImmune president Peter Greenleaf a director.
Greenleaf brings 20 years of biopharma experience to the board of directors. He is CEO of Sucampo Pharmaceuticals and a board member of Histogenics Corporation, a regenerative medicine company. He worked at MedImmune from 2006 to 2013, becoming CCO and later president and overseeing the sale of the company to AstraZeneca for $15.6 billion in 2007.
